- NEWS FEATURE
How a pioneering diabetes drug offers hope for preventing autoimmune disorders

Student Mikayla Olsten received the antibody therapy teplizumab in 2016, which has kept her from developing symptoms of type 1 diabetes. Credit: Natalie Behring for Nature
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 614, 404-406 (2023)
doi: https://doi.org/10.1038/d41586-023-00400-x
References
Sims, E. K. et al. Sci. Transl. Med. 13, eabc8980 (2021).
Herold, K. C. et al. N. Engl. J. Med. 381, 603–613 (2019).
Kung, P. C., Goldstein, G., Reinherz, E. L. & Schlossman, S. F. Science 206, 347–379 (1979).
Herold, K. C. et al. Clin. Immunol. 132, 166–173 (2009).
Sherry, N. et al. Lancet 378, 487–497 (2011).
Aronson, R. et al. Diab. Care 37, 2746–2754 (2014).
Long, A. S. et al. Sci. Immunol. 1, eaai7793 (2016).
Pagni, P. P. et al. Diabetes 71, 157–169 (2022).
Bonifacio, E. et al. JAMA 313, 1541–1549 (2015).
Rech, J. et al. Ann. Rheum. Dis. 81 (Suppl. 1), 526-527 (2022).
Okuda, D. T. et al. Ann. Neurol. https://doi.org/10.1002/ana.26555 (2022).
Ziegler, A.-G. et al. JAMA 323, 339–351 (2020).